U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubChem Compound

Items: 13

1.
Chronic hypoxia impairs skeletal muscle repair via HIF‐2α stabilization
Amelia Yin, Wenyan Fu, Anthony Elengickal, Joonhee Kim, Yang Liu, Anne Bigot, Kamal Mamchaoui, Jarrod A. Call, Hang Yin
J Cachexia Sarcopenia Muscle. 2024 Apr; 15(2): 631–645. Published online 2024 Feb 9. doi: 10.1002/jcsm.13436
PMCID:
PMC10995261
AbstractArticlePDF–6.9M
2.
Activity of a first‑in‑class oral HIF2‑alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma
Roy Strowd, Benjamin Ellingson, Catalina Raymond, Jingwen Yao, Patrick Y. Wen, Manmeet Ahluwalia, Anna Piotrowski, Arati Desai, Jennifer L. Clarke, Frank S. Lieberman, Serena Desideri, L. Burt Nabors, Xiaobu Ye, Stuart Grossman
J Neurooncol. Author manuscript; available in PMC 2024 Feb 13.
Published in final edited form as: J Neurooncol. 2023 Oct; 165(1): 101–112. Published online 2023 Oct 21. doi: 10.1007/s11060-023-04456-7
PMCID:
PMC10863646
AbstractArticlePDF–1.0M
3.
Differential effects of HIF2α antagonist and HIF2α silencing in renal cancer and sensitivity to repurposed drugs
Esther Arnaiz, Ana Miar, Esther Bridges, Naveen Prasad, Stephanie B. Hatch, Daniel Ebner, Charles H. Lawrie, Adrian L. Harris
BMC Cancer. 2021; 21: 896. Published online 2021 Aug 5. doi: 10.1186/s12885-021-08616-8
PMCID:
PMC8344147
AbstractArticlePDF–2.2M
4.
HIF-1α and HIF-2α redundantly promote retinal neovascularization in patients with ischemic retinal disease
Jing Zhang, Yaowu Qin, Mireya Martinez, Miguel Flores-Bellver, Murilo Rodrigues, Aumreetam Dinabandhu, Xuan Cao, Monika Deshpande, Yu Qin, Silvia Aparicio-Domingo, Yuan Rui, Stephany Y. Tzeng, Shaima Salman, Jin Yuan, Adrienne W. Scott, Jordan J. Green, M. Valeria Canto-Soler, Gregg L. Semenza, Silvia Montaner, Akrit Sodhi
J Clin Invest. 2021 Jun 15; 131(12): e139202. Published online 2021 Jun 15. doi: 10.1172/JCI139202
PMCID:
PMC8203455
AbstractArticlePDF–32M
5.
Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor
Jaclyn J. Renfrow, Michael H. Soike, James L. West, Shakti H. Ramkissoon, Linda Metheny-Barlow, Ryan T. Mott, Carol A. Kittel, Ralph B. D’Agostino, Jr., Stephen B. Tatter, Adrian W. Laxton, Mark B. Frenkel, Gregory A. Hawkins, Denise Herpai, Stephanie Sanders, Jann N. Sarkaria, Glenn J. Lesser, Waldemar Debinski, Roy E. Strowd
Sci Rep. 2020; 10: 15195. Published online 2020 Sep 16. doi: 10.1038/s41598-020-72290-2
PMCID:
PMC7495485
AbstractArticlePDF–2.5M
6.
Marked and rapid effects of pharmacological HIF-2α antagonism on hypoxic ventilatory control
Xiaotong Cheng, Maria Prange-Barczynska, James W. Fielding, Minghao Zhang, Alana L. Burrell, Joanna D.C.C. Lima, Luise Eckardt, Isobel L.A. Argles, Christopher W. Pugh, Keith J. Buckler, Peter A. Robbins, Emma J. Hodson, Richard K. Bruick, Lucy M. Collinson, Fraydoon Rastinejad, Tammie Bishop, Peter J. Ratcliffe
J Clin Invest. 2020 May 1; 130(5): 2237–2251. Published online 2020 Mar 23. doi: 10.1172/JCI133194
PMCID:
PMC7190921
AbstractArticlePDF–16M
7.
HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor in Clear Cell Renal Cell Carcinoma Patients
Kevin D. Courtney, Yuanqing Ma, Alberto Diaz de Leon, Alana Christie, Zhiqun Xie, Layton Woolford, Nirmish Singla, Allison Joyce, Haley Hill, Ananth J. Madhuranthakam, Qing Yuan, Yin Xi, Yue Zhang, Jenny Chang, Oluwatomilade Fatunde, Yull Arriaga, Arthur Frankel, Sanjeeva Kalva, Song Zhang, Tiffani McKenzie, Oscar Reig Torras, Robert A. Figlin, Brian I. Rini, Renée M. McKay, Payal Kapur, Tao Wang, Ivan Pedrosa, James Brugarolas
Clin Cancer Res. Author manuscript; available in PMC 2020 Aug 15.
Published in final edited form as: Clin Cancer Res. 2020 Feb 15; 26(4): 793–803. Published online 2019 Nov 14. doi: 10.1158/1078-0432.CCR-19-1459
PMCID:
PMC7024660
AbstractArticlePDF–1.6M
8.
Hypoxia-inducible factor 2α: a novel target in gliomas
Jaclyn J Renfrow, Michael H Soike, Waldemar Debinski, Shakti H Ramkissoon, Ryan T Mott, Mark B Frenkel, Jann N Sarkaria, Glenn J Lesser, Roy E Strowd
Future Med Chem. 2018 Sep; 10(18): 2227–2236. Published online 2018 Aug 9. doi: 10.4155/fmc-2018-0163
PMCID:
PMC6479274
AbstractArticlePDF–6.5M
9.
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma
Kevin D. Courtney, Jeffrey R. Infante, Elaine T. Lam, Robert A. Figlin, Brian I. Rini, James Brugarolas, Naseem J. Zojwalla, Ann M. Lowe, Keshi Wang, Eli M. Wallace, John A. Josey, Toni K. Choueiri
J Clin Oncol. 2018 Mar 20; 36(9): 867–874. Published online 2017 Dec 19. doi: 10.1200/JCO.2017.74.2627
PMCID:
PMC5946714
AbstractArticlePDF–1.0M
10.
PHGDH as a key enzyme for serine biosynthesis in HIF2α-targeting therapy for renal cell carcinoma
Hirofumi Yoshino, Nijiro Nohata, Kazutaka Miyamoto, Masaya Yonemori, Takashi Sakaguchi, Satoshi Sugita, Toshihiko Itesako, Satoshi Kofuji, Masayuki Nakagawa, Rajvir Dahiya, Hideki Enokida
Cancer Res. Author manuscript; available in PMC 2018 May 15.
Published in final edited form as: Cancer Res. 2017 Nov 15; 77(22): 6321–6329. Published online 2017 Sep 26. doi: 10.1158/0008-5472.CAN-17-1589
PMCID:
PMC5893502
AbstractArticlePDF–995K
11.
Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2α Inhibitor PT2385 In Vivo and In Vitro
Cen Xie, Xiaoxia Gao, Dongxue Sun, Youbo Zhang, Kristopher W. Krausz, Xuemei Qin, Frank J. Gonzalez
Drug Metab Dispos. 2018 Apr; 46(4): 336–345. Published online 2018 Apr. doi: 10.1124/dmd.117.079723
PMCID:
PMC5829541
AbstractArticlePDF–1.9M
12.
Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals
Junjie Xu, Longbo Zheng, Jiang Chen, Yin Sun, Hui Lin, Ren-an Jin, Minyue Tang, Xiao Liang, Xiujun Cai
Cell Death Dis. 2017 Oct; 8(10): e3095. Published online 2017 Oct 12. doi: 10.1038/cddis.2017.411
PMCID:
PMC5680567
AbstractArticlePDF–2.1M
13.
Targeting Renal Cell Carcinoma with a HIF-2 antagonist
Wenfang Chen, Haley Hill, Alana Christie, Min Soo Kim, Eboni Holloman, Andrea Pavia-Jimenez, Farrah Homayoun, Yuanqing Ma, Nirav Patel, Paul Yell, Guiyang Hao, Qurratulain Yousuf, Allison Joyce, Ivan Pedrosa, Heather Geiger, He Zhang, Jenny Chang, Kevin H. Gardner, Richard K. Bruick, Catherine Reeves, Tae Hyun Hwang, Kevin Courtney, Eugene Frenkel, Xiankai Sun, Naseem Zojwalla, Tai Wong, James P. Rizzi, Eli M. Wallace, John A. Josey, Yang Xie, Xian-Jin Xie, Payal Kapur, Renée M. McKay, James Brugarolas
Nature. Author manuscript; available in PMC 2017 May 3.
Published in final edited form as: Nature. 2016 Nov 3; 539(7627): 112–117. Published online 2016 Sep 5. doi: 10.1038/nature19796
PMCID:
PMC5340502
AbstractArticlePDF–5.5M

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

You are here: NCBI > Literature > PubMed Central (PMC)
Support Center